Loading...

O'brien, Susan M

TitleProfessor
InstitutionUniversity of California, Irvine
DepartmentMedicine
Address1001 Health Sciences Road
CA 92697-3950
Phone(714) 456-7511
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Lee JS, Roberts A, Juarez D, Vo TT, Bhatt S, Herzog LO, Mallya S, Bellin RJ, Agarwal SK, Salem AH, Xu T, Jia J, Li L, Hanna JR, Davids MS, Fleischman AG, O'Brien S, Lam LT, Leverson JD, Letai A, Schatz JH, Fruman DA. Statins enhance efficacy of venetoclax in blood cancers. Sci Transl Med. 2018 Jun 13; 10(445). PMID: 29899021.
      View in: PubMed
    2. Jones J, Mato A, Coutre S, Byrd JC, Furman RR, Hillmen P, Osterborg A, Tam C, Stilgenbauer S, Wierda WG, Heerema NA, Eckert K, Clow F, Zhou C, Chu AD, James DF, O'Brien S. Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials. Br J Haematol. 2018 Jun 05. PMID: 29873072.
      View in: PubMed
    3. Thompson PA, Peterson CB, Strati P, Jorgensen J, Keating MJ, O'Brien S, Ferrajoli A, Burger JA, Estrov Z, Jain N, Kadia TM, Borthakur G, DiNardo CD, Daver N, Jabbour E, Wierda WG. Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. Leukemia. 2018 Apr 17. PMID: 29769624.
      View in: PubMed
    4. Kantarjian HM, DiNardo CD, Nogueras-Gonzalez GM, Kadia TM, Jabbour E, Bueso-Ramos CE, O'Brien S, Konopleva M, Jain NB, Daver NG, Shpall EJ, Champlin RE, Simkins A, Garcia-Manero G, Keating MJ, Huang X, Cortes JE, Pierce SA, Ravandi F, Freireich EJ. Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. Cancer. 2018 Apr 12. PMID: 29645075.
      View in: PubMed
    5. O'Brien S, Jaglowski S, Byrd JC, Bannerji R, Blum KA, Fox CP, Furman RR, Hillmen P, Kipps TJ, Montillo M, Sharman J, Suzuki S, James DF, Chu AD, Coutre SE. Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. JAMA Oncol. 2018 Feb 22. PMID: 29470582.
      View in: PubMed
    6. Strati P, Ferrajoli A, Wierda WG, Jain N, Thompson PA, O'Brien S, Rezvani K, Kantarjian HM, Burger JA, Hinojosa CO, Keating MJ, Estrov Z. Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia. Leukemia. 2018 Feb 20. PMID: 29479067.
      View in: PubMed
    7. O'Brien S. Rituximab maintenance is efficacious, but is it useful? Lancet Haematol. 2018 Feb; 5(2):e58-e59. PMID: 29406147.
      View in: PubMed
    8. O'Brien S. Highlights in chronic lymphocytic leukemia from the 2017 American Society of Hematology Annual Meeting: commentary. Clin Adv Hematol Oncol. 2018 Jan; 16 Suppl 2(1):16-19. PMID: 29742092.
      View in: PubMed
    9. Strati P, Keating MJ, Burger JA, O'Brien S, Wierda WG, Estrov Z, Zacharian G, Ferrajoli A. Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia. Haematologica. 2017 Dec; 102(12):e494-e496. PMID: 28798068.
      View in: PubMed
    10. Short NJ, Kantarjian H, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien S, Cortes JE, Jabbour E. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2018 Apr; 59(4):813-820. PMID: 28718728.
      View in: PubMed
    11. Jabbour E, Short NJ, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien S, Cortes JE, Kantarjian H. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer. 2017 Nov 15; 123(22):4430-4439. PMID: 28708931.
      View in: PubMed
    12. Kantarjian HM, DeAngelo DJ, Advani AS, Stelljes M, Kebriaei P, Cassaday RD, Merchant AA, Fujishima N, Uchida T, Calbacho M, Ejduk AA, O'Brien S, Jabbour EJ, Zhang H, Sleight BJ, Vandendries ER, Marks DI. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematol. 2017 Aug; 4(8):e387-e398. PMID: 28687420.
      View in: PubMed
    13. O'Brien S. Highlights From the XVII International Workshop on Chronic Lymphocytic Leukemia: Commentary. Clin Adv Hematol Oncol. 2017 Jul; 15 Suppl 6(7):13-15. PMID: 28837123.
      View in: PubMed
    14. Tran PN, O'Brien S. The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia. Expert Opin Drug Saf. 2017 Sep; 16(9):1079-1088. PMID: 28627951.
      View in: PubMed
    15. Short NJ, Kantarjian HM, Ko H, Khoury JD, Ravandi F, Thomas DA, Garcia-Manero G, Khouri M, Cortes JE, Wierda WG, Verstovsek S, Estrov Z, Ferrajoli A, Thompson PA, Pierce S, O'Brien S, Jabbour E. Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma. Am J Hematol. 2017 06; 92(6):E114-E117. PMID: 28295472.
      View in: PubMed
    16. Jones JA, Hillmen P, Coutre S, Tam C, Furman RR, Barr PM, Schuster SJ, Kipps TJ, Flinn IW, Jaeger U, Burger JA, Cheng M, Ninomoto J, James DF, Byrd JC, O'Brien S. Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib. Br J Haematol. 2017 07; 178(2):286-291. PMID: 28397242.
      View in: PubMed
    17. Jain N, Balakrishnan K, Ferrajoli A, O'Brien S, Burger JA, Kadia TM, Cortes JE, Ayres ML, Tambaro FP, Keating MJ, Gandhi V, Wierda WG. A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL. Oncotarget. 2017 Mar 28; 8(13):22104-22112. PMID: 27655665.
      View in: PubMed
    18. Rytting ME, Jabbour EJ, O'Brien S, Kantarjian HM. Acute lymphoblastic leukemia in adolescents and young adults. Cancer. 2017 Jul 01; 123(13):2398-2403. PMID: 28328172.
      View in: PubMed
    19. Thompson PA, Stingo F, Keating MJ, Wierda WG, O'Brien S, Estrov Z, Ledesma C, Rezvani K, Qazilbash M, Shah N, Parmar S, Popat U, Anderlini P, Yago N, Ciurea SO, Kebriaei P, Champlin R, Shpall EJ, Hosing CM. Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival. Br J Haematol. 2017 05; 177(4):567-577. PMID: 28295181.
      View in: PubMed
    20. Fruman DA, O'Brien S. Cancer: A targeted treatment with off-target risks. Nature. 2017 02 23; 542(7642):424-425. PMID: 28199308.
      View in: PubMed
    21. Short NJ, Kantarjian HM, Sasaki K, Ravandi F, Ko H, Cameron Yin C, Garcia-Manero G, Cortes JE, Garris R, O'Brien S, Patel K, Khouri M, Thomas D, Jain N, Kadia TM, Daver NG, Benton CB, Issa GC, Konopleva M, Jabbour E. Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. Am J Hematol. 2017 Mar; 92(3):238-243. PMID: 28006851.
      View in: PubMed
    22. Ravandi F, Othus M, O'Brien S, Forman SJ, Ha CS, Wong JYC, Tallman MS, Paietta E, Racevskis J, Uy GL, Horowitz M, Takebe N, Little R, Borate U, Kebriaei P, Kingsbury L, Kantarjian HM, Radich JP, Erba HP, Appelbaum FR. US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL. Blood Adv. 2016 Dec 27; 1(3):250-259. PMID: 29046900.
      View in: PubMed
    23. O'Brien S. Considerations in the frontline treatment of chronic lymphocytic leukemia. Clin Adv Hematol Oncol. 2016 Dec; 14(12):970-973. PMID: 28212359.
      View in: PubMed
    24. Chen Q, Jain N, Ayer T, Wierda WG, Flowers CR, O'Brien S, Keating MJ, Kantarjian HM, Chhatwal J. Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States. J Clin Oncol. 2017 Jan 10; 35(2):166-174. PMID: 27870563.
      View in: PubMed
    25. Yang W, Tran P, Khan Z, Rezk S, O'Brien S. MLL-rearranged mixed phenotype acute leukemia masquerading as B-cell ALL. Leuk Lymphoma. 2017 06; 58(6):1498-1501. PMID: 27774846.
      View in: PubMed
    26. Koller PB, Kantarjian HM, Nogueras-Gonzalez GM, Jabbour E, Verstovsek S, Borthakur G, Estrov Z, Wierda WG, Garcia-Manero G, Ferrajoli A, Ravandi F, O'Brien S, Cortes JE. Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship. Cancer. 2017 Feb 15; 123(4):609-616. PMID: 27763690.
      View in: PubMed
    27. Issa GC, Kantarjian HM, Yin CC, Qiao W, Ravandi F, Thomas D, Short NJ, Sasaki K, Garcia-Manero G, Kadia TM, Cortes JE, Daver N, Borthakur G, Jain N, Konopleva M, Khouri I, Kebriaei P, Champlin RE, Pierce S, O'Brien S, Jabbour E. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. Cancer. 2017 Feb 01; 123(3):459-467. PMID: 27696391.
      View in: PubMed
    28. O'Brien S, Jones JA, Coutre SE, Mato AR, Hillmen P, Tam C, Österborg A, Siddiqi T, Thirman MJ, Furman RR, Ilhan O, Keating MJ, Call TG, Brown JR, Stevens-Brogan M, Li Y, Clow F, James DF, Chu AD, Hallek M, Stilgenbauer S. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016 Oct; 17(10):1409-1418. PMID: 27637985.
      View in: PubMed
    29. Jabbour E, Short NJ, Jorgensen JL, Yilmaz M, Ravandi F, Wang SA, Thomas DA, Khoury J, Champlin RE, Khouri I, Kebriaei P, O'Brien S, Garcia-Manero G, Cortes JE, Sasaki K, Dinardo CD, Kadia TM, Jain N, Konopleva M, Garris R, Kantarjian HM. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Cancer. 2017 01 01; 123(2):294-302. PMID: 27602508.
      View in: PubMed
    30. Jeyakumar D, O'Brien S. B cell receptor inhibition as a target for CLL therapy. Best Pract Res Clin Haematol. 2016 Mar; 29(1):2-14. PMID: 27742069.
      View in: PubMed
    31. Short NJ, Kantarjian HM, Sasaki K, Cortes JE, Ravandi F, Thomas DA, Garcia-Manero G, Khouri I, Kebriaei P, Champlin RE, Pierce S, Issa GC, Konopleva M, Kadia TM, Bueso-Ramos C, Khoury JD, Jain N, O'Brien S, Jabbour E. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer. 2016 Dec 15; 122(24):3812-3820. PMID: 27508525.
      View in: PubMed
    32. Sasaki K, Jabbour EJ, Ravandi F, Short NJ, Thomas DA, Garcia-Manero G, Daver NG, Kadia TM, Konopleva MY, Jain N, Issa GC, Jeanis V, Moore HG, Garris RS, Pemmaraju N, Cortes JE, O'Brien S, Kantarjian HM. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. Cancer. 2016 Dec 01; 122(23):3650-3656. PMID: 27479888.
      View in: PubMed
    33. Rytting ME, Jabbour EJ, Jorgensen JL, Ravandi F, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Borthakur G, Garris R, Wang S, Pierce S, Schroeder K, Kornblau SM, Thomas DA, Cortes JE, O'Brien S, Kantarjian HM. Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen. Am J Hematol. 2016 Aug; 91(8):819-23. PMID: 27178680.
      View in: PubMed
    34. Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, Gökbuget N, O'Brien S, Wang K, Wang T, Paccagnella ML, Sleight B, Vandendries E, Advani AS. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med. 2016 Aug 25; 375(8):740-53. PMID: 27292104.
      View in: PubMed
    35. Short NJ, Jabbour E, Sasaki K, Patel K, O'Brien S, Cortes JE, Garris R, Issa GC, Garcia-Manero G, Luthra R, Thomas D, Kantarjian H, Ravandi F. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2016 07 28; 128(4):504-7. PMID: 27235138; PMCID: PMC4965905 [Available on 07/28/17].
    36. Thompson PA, Stingo F, Keating MJ, Ferrajoli A, Burger JA, Wierda WG, Kadia TM, O'Brien S. Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity. Cancer. 2016 08 15; 122(16):2505-11. PMID: 27182988.
      View in: PubMed
    37. Barr PM, Saylors GB, Spurgeon SE, Cheson BD, Greenwald DR, O'Brien S, Liem AK, Mclntyre RE, Joshi A, Abella-Dominicis E, Hawkins MJ, Reddy A, Di Paolo J, Lee H, He J, Hu J, Dreiling LK, Friedberg JW. Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. Blood. 2016 05 19; 127(20):2411-5. PMID: 26968534; PMCID: PMC4874222.
    38. Short NJ, Kantarjian HM, Jabbour EJ, O'Brien S, Faderl S, Burger JA, Garris R, Qiao W, Huang X, Jain N, Konopleva M, Kadia TM, Daver N, Borthakur G, Cortes JE, Ravandi F. Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia. Am J Hematol. 2016 Jun; 91(4):385-9. PMID: 26800008.
      View in: PubMed
    39. Chiaretti S, Gianfelici V, O'Brien S, Mullighan CG. Advances in the Genetics and Therapy of Acute Lymphoblastic Leukemia. Am Soc Clin Oncol Educ Book. 2016; 35:e314-22. PMID: 27249738.
      View in: PubMed
    40. Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR, Hillmen P, Stephens DM, Ghia P, Barrientos JC, Pagel JM, Woyach J, Johnson D, Huang J, Wang X, Kaptein A, Lannutti BJ, Covey T, Fardis M, McGreivy J, Hamdy A, Rothbaum W, Izumi R, Diacovo TG, Johnson AJ, Furman RR. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2016 Jan 28; 374(4):323-32. PMID: 26641137; PMCID: PMC4862586.
    41. Thompson PA, O'Brien S, Xiao L, Wang X, Burger JA, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WG. ß2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia. Cancer. 2016 Feb 15; 122(4):565-73. PMID: 26588193; PMCID: PMC4813299 [Available on 02/15/17].
    42. Ravandi F, Jorgensen JL, O'Brien S, Jabbour E, Thomas DA, Borthakur G, Garris R, Huang X, Garcia-Manero G, Burger JA, Ferrajoli A, Wierda W, Kadia T, Jain N, Wang SA, Konoplev S, Kebriaei P, Champlin RE, McCue D, Estrov Z, Cortes JE, Kantarjian HM. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol. 2016 Feb; 172(3):392-400. PMID: 26492205; PMCID: PMC4826052 [Available on 02/01/17].
    43. Thompson PA, Tam CS, O'Brien S, Wierda WG, Stingo F, Plunkett W, Smith SC, Kantarjian HM, Freireich EJ, Keating MJ. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2016 Jan 21; 127(3):303-9. PMID: 26492934; PMCID: PMC4760129.
    44. Sasaki K, Kantarjian HM, Jain P, Jabbour EJ, Ravandi F, Konopleva M, Borthakur G, Takahashi K, Pemmaraju N, Daver N, Pierce SA, O'Brien S, Cortes JE. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. Cancer. 2016 Jan 15; 122(2):238-48. PMID: 26479889; PMCID: PMC4707980 [Available on 01/15/17].
    45. O'Brien S, Lamanna N, Kipps TJ, Flinn I, Zelenetz AD, Burger JA, Keating M, Mitra S, Holes L, Yu AS, Johnson DM, Miller LL, Kim Y, Dansey RD, Dubowy RL, Coutre SE. A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. Blood. 2015 Dec 17; 126(25):2686-94. PMID: 26472751; PMCID: PMC4732760.
    46. Ravandi F, O'Brien S, Cortes JE, Thomas DM, Garris R, Faderl S, Burger JA, Rytting ME, Ferrajoli A, Wierda WG, Verstovsek S, Champlin R, Kebriaei P, McCue DA, Huang X, Jabbour E, Garcia-Manero G, Estrov Z, Kantarjian HM. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015 Dec 01; 121(23):4158-64. PMID: 26308885; PMCID: PMC4666803 [Available on 12/01/16].
    47. Short NJ, Keating MJ, Wierda WG, Faderl S, Ferrajoli A, Estrov Z, Smith SC, O'Brien S. Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia. Cancer. 2015 Nov 01; 121(21):3869-76. PMID: 26218678; PMCID: PMC4824541 [Available on 11/01/16].
    48. Thompson PA, O'Brien S, Wierda WG, Ferrajoli A, Stingo F, Smith SC, Burger JA, Estrov Z, Jain N, Kantarjian HM, Keating MJ. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer. 2015 Oct 15; 121(20):3612-21. PMID: 26193999; PMCID: PMC4866653 [Available on 10/15/16].
    49. O'Brien S. VIII. Treatment of chronic lymphocytic leukaemia, where are we heading? Hematol Oncol. 2015 Jun; 33 Suppl 1:46-9. PMID: 26062054.
      View in: PubMed
    50. Coutré SE, Barrientos JC, Brown JR, de Vos S, Furman RR, Keating MJ, Li D, O'Brien S, Pagel JM, Poleski MH, Sharman JP, Yao NS, Zelenetz AD. Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma. 2015; 56(10):2779-86. PMID: 25726955; PMCID: PMC4732460.
    51. Thompson PA, Rozovski U, Keating MJ, Stingo F, Smith SC, Wierda WG, Falchi L, O'Brien S, Estrov Z, Burger JA, Ferrajoli A. The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy - the MD Anderson Cancer Center experience. Br J Haematol. 2015 Mar 30. PMID: 25824652.
      View in: PubMed
    52. Sanford DS, Wierda WG, Burger JA, Keating MJ, O'Brien S. Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice. Clin Lymphoma Myeloma Leuk. 2015 Jul; 15(7):385-91. PMID: 25817936; PMCID: PMC4905707.
    53. Rytting ME, Thomas DA, O'Brien S, Ravandi-Kashani F, Jabbour EJ, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Cortes JE, Borthakur G, Garris R, Cardenas-Turanzas M, Schroeder K, Jorgensen JL, Kornblau SM, Kantarjian HM. Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer. 2014 Dec 01; 120(23):3660-8. PMID: 25042398; PMCID: PMC4239168.
    54. Strati P, Keating MJ, O'Brien S, Ferrajoli A, Burger J, Faderl S, Tambaro FP, Jain N, Wierda WG. Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion. Haematologica. 2014 Aug; 99(8):1350-5. PMID: 24859876; PMCID: PMC4116834.
    55. Wodarz D, Garg N, Komarova NL, Benjamini O, Keating MJ, Wierda WG, Kantarjian H, James D, O'Brien S, Burger JA. Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib. Blood. 2014 Jun 26; 123(26):4132-5. PMID: 24829205; PMCID: PMC4123432.
    56. Strati P, Keating MJ, O'Brien S, Burger J, Ferrajoli A, Jain N, Tambaro FP, Estrov Z, Jorgensen J, Challagundla P, Faderl SH, Wierda WG. Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood. 2014 Jun 12; 123(24):3727-32. PMID: 24705492; PMCID: PMC4067501.
    57. Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Stilgenbauer S, Cramer P, Aiello M, Johnson DM, Miller LL, Li D, Jahn TM, Dansey RD, Hallek M, O'Brien S. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014 Mar 13; 370(11):997-1007. PMID: 24450857; PMCID: PMC4161365.
    58. Brown JR, Porter DL, O'Brien S. Novel treatments for chronic lymphocytic leukemia and moving forward. Am Soc Clin Oncol Educ Book. 2014; e317-25. PMID: 24857119.
      View in: PubMed
    59. O'Brien S, Furman RR, Byrd JC, Smith A. Clinical roundtable monograph: unmet needs in the treatment of chronic lymphocytic leukemia: integrating a targeted approach. Clin Adv Hematol Oncol. 2014 Jan; 12(1 Suppl 3):1-13. PMID: 24870382.
      View in: PubMed
    60. O'Brien S. Targeted agents in chronic lymphocytic leukemia. Clin Adv Hematol Oncol. 2014 Jan; 12 Suppl 3(1):9-11. PMID: 25856007.
      View in: PubMed
    61. O'Brien S. Update on ibrutinib. Clin Adv Hematol Oncol. 2013 Nov; 11(11):735-7. PMID: 24896547.
      View in: PubMed
    62. Badoux XC, Keating MJ, Wen S, Wierda WG, O'Brien S, Faderl S, Sargent R, Burger JA, Ferrajoli A. Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2013 Feb 10; 31(5):584-91. PMID: 23270003; PMCID: PMC4878047.
    63. Cheson BD, Byrd JC, Rai KR, Kay NE, O'Brien S, Flinn IW, Wiestner A, Kipps TJ. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol. 2012 Aug 10; 30(23):2820-2. PMID: 22778323; PMCID: PMC3410400.
    64. Badoux XC, Keating MJ, Wen S, Lee BN, Sivina M, Reuben J, Wierda WG, O'Brien S, Faderl S, Kornblau SM, Burger JA, Ferrajoli A. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood. 2011 Sep 29; 118(13):3489-98. PMID: 21725050; PMCID: PMC4123422.
    65. Badoux XC, Keating MJ, Wang X, O'Brien S, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG. Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia. Blood. 2011 Aug 25; 118(8):2085-93. PMID: 21670470; PMCID: PMC4123326.
    66. Badoux XC, Keating MJ, Wang X, O'Brien S, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood. 2011 Mar 17; 117(11):3016-24. PMID: 21245487; PMCID: PMC4123386.
    67. Wierda WG, Kipps TJ, Keating MJ, Brown JR, Gribben JG, Browning M, Rassenti LZ, Greaves AW, Neuberg D, O'Brien S. Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia. Cancer. 2011 Jan 01; 117(1):116-24. PMID: 20806349; PMCID: PMC4535917.
    68. Bashir Q, De Lima MJ, McMannis JD, Garcia-Manero G, Shpall E, Kantarjian H, Cortes JE, O'Brien S, Jones D, Qazilbash M, Wei W, Giralt SA, Champlin RE, Hosing C. Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy. Leuk Lymphoma. 2010 Aug; 51(8):1478-84. PMID: 20658954; PMCID: PMC4188823.
    69. Schiller GJ, O'Brien S, Pigneux A, Deangelo DJ, Vey N, Kell J, Solomon S, Stuart RK, Karsten V, Cahill AL, Albitar MX, Giles FJ. Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia. J Clin Oncol. 2010 Feb 10; 28(5):815-21. PMID: 20026800.
      View in: PubMed
    70. O'Brien S, Claxton DF, Crump M, Faderl S, Kipps T, Keating MJ, Viallet J, Cheson BD. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood. 2009 Jan 08; 113(2):299-305. PMID: 18931344; PMCID: PMC4968372.
    71. Ferrajoli A, Lee BN, Schlette EJ, O'Brien S, Gao H, Wen S, Wierda WG, Estrov Z, Faderl S, Cohen EN, Li C, Reuben JM, Keating MJ. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008 Jun 01; 111(11):5291-7. PMID: 18334676; PMCID: PMC4082321.
    72. Ferrajoli A, Wierda WG, LaPushin R, O'Brien S, Faderl S, Browning ML, Keating MJ. Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia. Eur J Haematol. 2008 Apr; 80(4):296-8. PMID: 18182081.
      View in: PubMed
    73. O'Brien S, Keating MJ, Mocarski ES. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin Lymphoma Myeloma. 2006 Sep; 7(2):125-30. PMID: 17026823.
      View in: PubMed
    74. Yee KW, O'Brien S. Chronic lymphocytic leukemia: diagnosis and treatment. Mayo Clin Proc. 2006 Aug; 81(8):1105-29. PMID: 16901035.
      View in: PubMed
    75. Thomas DA, Giles FJ, Albitar M, Cortes JE, Verstovsek S, Faderl S, O'Brien S, Garcia-Manero G, Keating MJ, Pierce S, Zeldis J, Kantarjian HM. Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer. 2006 May 01; 106(9):1974-84. PMID: 16583431.
      View in: PubMed
    76. Wierda WG, O'Brien S. Initial therapy for patients with chronic lymphocytic leukemia. Semin Oncol. 2006 Apr; 33(2):202-9. PMID: 16616067.
      View in: PubMed
    77. Albitar M, Vose JM, Johnson MM, Do KA, Day A, Jilani I, Kantarjian H, Keating M, O'Brien S, Verstovsek S, Armitage JO, Giles FJ. Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease. Leuk Res. 2007 Feb; 31(2):139-45. PMID: 16545870.
      View in: PubMed
    78. Yee KW, O'Brien S. Emerging drugs for chronic lymphocytic leukaemia. Expert Opin Emerg Drugs. 2006 Mar; 11(1):167-89. PMID: 16503834.
      View in: PubMed
    79. Ravandi F, Jorgensen JL, O'Brien S, Verstovsek S, Koller CA, Faderl S, Giles FJ, Ferrajoli A, Wierda WG, Odinga S, Huang X, Thomas DA, Freireich EJ, Jones D, Keating MJ, Kantarjian HM. Eradication of minimal residual disease in hairy cell leukemia. Blood. 2006 Jun 15; 107(12):4658-62. PMID: 16497968.
      View in: PubMed
    80. Yee KW, Cortes J, Ferrajoli A, Garcia-Manero G, Verstovsek S, Wierda W, Thomas D, Faderl S, King I, O'brien SM, Jeha S, Andreeff M, Cahill A, Sznol M, Giles FJ. Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome. Leuk Res. 2006 Jul; 30(7):813-22. PMID: 16478631.
      View in: PubMed
    81. Giles FJ, Bellamy WT, Estrov Z, O'Brien S, Verstovsek S, Ravandi F, Beran M, Bycott P, Pithavala Y, Steinfeldt H, Reich SD, List AF, Yee KW. The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Leuk Res. 2006 Jul; 30(7):801-11. PMID: 16332390.
      View in: PubMed
    82. O'Brien S, Cunningham CC, Golenkov AK, Turkina AG, Novick SC, Rai KR. Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. J Clin Oncol. 2005 Oct 20; 23(30):7697-702. PMID: 16186597.
      View in: PubMed
    83. Yee KW, Hagey A, Verstovsek S, Cortes J, Garcia-Manero G, O'Brien S, Faderl S, Thomas D, Wierda W, Kornblau S, Ferrajoli A, Albitar M, McKeegan E, Grimm DR, Mueller T, Holley-Shanks RR, Sahelijo L, Gordon GB, Kantarjian HM, Giles FJ. Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2005 Sep 15; 11(18):6615-24. PMID: 16166440.
      View in: PubMed
    84. Yee KW, O'Brien S, Giles FJ. Richter's syndrome: biology and therapy. Cancer J. 2005 May-Jun; 11(3):161-74. PMID: 16053658.
      View in: PubMed
    85. Giles FJ, Kantarjian HM, Cortes JE, Faderl S, Verstovsek S, Thomas D, Garcia-Manero G, Wierda W, Ferrajoli A, Kornblau S, Mattiuzzi GN, Tsimberidou AM, Albitar M, O'Brien S, Estey E. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes. Leuk Res. 2005 Jun; 29(6):649-52. PMID: 15863204.
      View in: PubMed
    86. Yee KW, O'Brien S, Giles FJ. An update on the management of chronic lymphocytic leukaemia. Expert Opin Pharmacother. 2004 Jul; 5(7):1535-54. PMID: 15212604.
      View in: PubMed
    87. Giles FJ, Vose JM, Do KA, Johnson MM, Manshouri T, Bociek G, Bierman PJ, O'Brien S, Kantarjian HM, Armitage JO, Albitar M. Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma. Leuk Res. 2004 Jun; 28(6):595-604. PMID: 15120936.
      View in: PubMed
    88. Giles FJ, Cortes JE, Kantarjian HM, O'Brien S. Accelerated and blastic phases of chronic myelogenous leukemia. Hematol Oncol Clin North Am. 2004 Jun; 18(3):753-74, xii. PMID: 15271404.
      View in: PubMed
    89. Cortes JE, O'Brien S, Giles F, Alvarez RH, Talpaz M, Kantarjian HM. Investigational strategies in chronic myelogenous leukemia. Hematol Oncol Clin North Am. 2004 Jun; 18(3):619-39, ix. PMID: 15271396.
      View in: PubMed
    90. Giles FJ, Cortes JE, Kantarjian HM, O'Brien S, Estey E, Beran M. A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia. Leuk Res. 2004 Apr; 28(4):353-7. PMID: 15109534.
      View in: PubMed
    91. Ferrajoli A, O'Brien S. Treatment of chronic lymphocytic leukemia. Semin Oncol. 2004 Apr; 31(2 Suppl 4):60-5. PMID: 15124136.
      View in: PubMed
    92. Weiser MA, Cabanillas ME, Konopleva M, Thomas DA, Pierce SA, Escalante CP, Kantarjian HM, O'Brien S. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. Cancer. 2004 Mar 15; 100(6):1179-85. PMID: 15022284.
      View in: PubMed
    93. O'Brien S, Kantarjian HM, Thomas DA, Cortes J, Giles FJ, Wierda WG, Koller CA, Ferrajoli A, Browning M, Lerner S, Albitar M, Keating MJ. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer. 2003 Dec 15; 98(12):2657-63. PMID: 14669286.
      View in: PubMed
    94. Giles FJ, Vose JM, Do KA, Johnson MM, Manshouri T, Bociek G, Bierman PJ, O'Brien S, Keating MJ, Kantarjian HM, Armitage JO, Albitar M. Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease. Br J Haematol. 2003 Dec; 123(5):850-7. PMID: 14632776.
      View in: PubMed
    95. Giles FJ, Feldman EJ, Roboz GJ, Larson RA, Mamus SW, Cortes JE, Verstovsek S, Faderl S, Talpaz M, Beran M, Albitar M, O'Brien S, Kantarjian HM. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase. Leuk Res. 2003 Dec; 27(12):1091-6. PMID: 12921945.
      View in: PubMed
    96. Tsimberidou AM, Giles FJ, Kantarjian HM, Keating MJ, O'Brien S. Anti-B4 blocked ricin post chemotherapy in patients with chronic lymphocytic leukemia--long-term follow-up of a monoclonal antibody-based approach to residual disease. Leuk Lymphoma. 2003 Oct; 44(10):1719-25. PMID: 14692524.
      View in: PubMed
    97. Ferrajoli A, O'Brien S, Cortes JE, Giles FJ, Thomas DA, Faderl S, Kurzrock R, Lerner S, Kontoyiannis DP, Keating MJ. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer. 2003 Aug 15; 98(4):773-8. PMID: 12910522.
      View in: PubMed
    98. Giles FJ, Shi GG, Cortes JE, Thomas D, Keating AR, Kantarjian HM, Keating MJ, O'Brien S. Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia. Cancer Chemother Pharmacol. 2003 Sep; 52(3):223-8. PMID: 12783199.
      View in: PubMed
    99. Tsimberidou AM, Colburn DE, Welch MA, Cortes JE, Verstovsek S, O'Brien S, Albitar M, Kantarjian HM, Giles FJ. Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders. Cancer Chemother Pharmacol. 2003 Sep; 52(3):229-34. PMID: 12783207.
      View in: PubMed
    100. Tsimberidou AM, Kantarjian HM, Cortes J, Thomas DA, Faderl S, Garcia-Manero G, Verstovsek S, Ferrajoli A, Wierda W, Alvarado Y, O'Brien S, Albitar M, Keating MJ, Giles FJ. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer. 2003 Apr 01; 97(7):1711-20. PMID: 12655528.
      View in: PubMed
    101. Giles FJ, Stopeck AT, Silverman LR, Lancet JE, Cooper MA, Hannah AL, Cherrington JM, O'Farrell AM, Yuen HA, Louie SG, Hong W, Cortes JE, Verstovsek S, Albitar M, O'Brien S, Kantarjian HM, Karp JE. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood. 2003 Aug 01; 102(3):795-801. PMID: 12649163.
      View in: PubMed
    102. Giles FJ, Faderl S, Thomas DA, Cortes JE, Garcia-Manero G, Douer D, Levine AM, Koller CA, Jeha SS, O'Brien S, Estey EH, Kantarjian HM. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. J Clin Oncol. 2003 Mar 15; 21(6):1050-6. PMID: 12637470.
      View in: PubMed
    103. O'Brien S, Kantarjian H, Radich J. Update: chronic myelogenous leukemia clinical practice guidelines. J Natl Compr Canc Netw. 2003 Jan; 1 Suppl 1:S29-40. PMID: 19795574.
      View in: PubMed
    104. Manshouri T, Do KA, Wang X, Giles FJ, O'Brien S, Saffer H, Thomas D, Jilani I, Kantarjian HM, Keating MJ, Albitar M. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood. 2003 Apr 01; 101(7):2507-13. PMID: 12446458.
      View in: PubMed
    105. Tsimberidou AM, O'Brien S, Cortes JE, Faderl S, Andreeff M, Kantarjian HM, Keating MJ, Giles FJ. Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders. Leuk Lymphoma. 2002 Apr; 43(4):767-72. PMID: 12153163.
      View in: PubMed
    106. Giles FJ, Garcia-Manero G, Cortes JE, Baker SD, Miller CB, O'Brien S, Thomas DA, Andreeff M, Bivins C, Jolivet J, Kantarjian HM. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. J Clin Oncol. 2002 Feb 01; 20(3):656-64. PMID: 11821445.
      View in: PubMed